Moreover, we find that low SENP6 expression is associated with poor outcomes of DLBCL patients after standard treatment and that the SENP6 status affects the sensitivity of DLBCL cells to chemotherapy. The gene discussed is SENP6; the disease is diffuse large B-cell lymphoma.